Many methods to measure pharmacodynamic endpoints are currently available, for instance, enzyme-linked immunosorbent assay (ELISA), reverse transcription-polymerase chain reaction (RT-PCR), and western blotting. Measuring these endpoints is a crucial step in optimizing your compound to transition into clinical trials. However, when it comes to sensitivity, accuracy, and economic efficiency, Meso Scale Discovery (MSD) biomarker assays prove to be an advantageous option to further develop your compound. The platform comprises of different assay kits that allow rapid measurement of the levels of a specific biomarker within a single, small-volume sample.
How it works:
The MSD technology leverages electrochemiluminescence technology through parallel processing of biological assays and provides a quantitative measure of the analyte with your sample. There are over 500 assay panels, custom panels, and reagent kits enabling for a large variety of protein analyses. You can view the whole list of available MSD assays here
If your analyte is not already validated within one of the available kits, InnoSer can provide you with the expertise coupled with validation services enabling you to assess your specific analyte. By introducing biomarker discovery early on in your research through this customizable approach you will increase the translational power of your preclinical research.
Benefits:
With MSD’s novel technology, we now have the capabilities to provide greater sensitivity, precision, reproducibility, and absolute quantification. These added benefits come with faster turnaround times for your results and lower costs than traditional methods like ELISA or Western Blot due to its multiplex system that allows an analysis of up to 10 markers in a single well.
With a wide range of applications, this analysis technique can be applied to many different study types adding value and saving time to a range of projects. The ready to use validated panels include:
- Cytokines & Chemokines
- Oncology
- Angiogenesis & Vascular analytes
- Bone Metabolism
- Cardiovascular
- Metabolism
- Inflammation
- Intracellular Signaling
- Neurodegeneration
- Toxicology
- GPCR-ligand binding proteins
- Immunology
- Growth factors
- Hypoxia
Through thorough preclinical investigation, we can increase the translatability of your lead compounds from the preclinical stage into clinical trials. Using a variety of techniques combined with the most appropriate readouts, InnoSer will work closely with you in providing expertise at every step of your drug development process.
Do you have more questions about how MSD technology could benefit your research?
Want to read more?
Choosing The Right ADPKD Model for Advancing your Rare Disease Research
To support the development of new therapies for autosomal dominant polycystic kidney disease, we offer a kidney-specific PKD1 knockout mouse model. The age-dependent nature of cyst formation allows for tailoring of the model, enabling researchers to choose the most...
A novel inflammation and fibrosis model in the field of NASH & drug repurposing
Nonalcoholic steatohepatitis Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) and is associated with disease progression and the development of cirrhosis. Given the high attrition rates, repurposing of 'old'...
InnoSer and Inficure Bio enter partnership to increase accessibility of translational liver inflammation & fibrosis mouse model
October 27th Diepenbeek, Belgium and Umeà, Sweden - InnoSer and Inficure Bio are announcing a strategic partnership to offer Inficure Bio’s spontaneous liver inflammation & fibrosis mouse model (NIF mouse) as part of InnoSer’s expanding cardiometabolic...